Chronic nicotine exposure attenuates methamphetamine-induced dopaminergic deficits

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 3, 2015, Pages 463-472

  Vieira Brock, Paula L ^a   McFadden, Lisa M ^a   Nielsen, Shannon M ^a   Ellis, Jonathan D ^a   Walters, Elliot T ^a   Stout, Kristen A ^a   McIntosh, J Michael ^b,c   Wilkins, Diana G ^b   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIBATIDINE; IODINE 125; METHAMPHETAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR ALPHA6BETA2; OMEGA CONOTOXIN MVIIA; UNCLASSIFIED DRUG; ALPHA6BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR; DOPAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; FUSED HETEROCYCLIC RINGS; NICOTINIC AGENT; PYRIDINE DERIVATIVE;

ADOLESCENCE; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; EXPOSURE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; AGING; ANIMAL; DEFICIENCY; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; ONSET AGE; SPRAGUE DAWLEY RAT;

AGE OF ONSET; AGING; ANIMALS; AUTORADIOGRAPHY; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; NICOTINE; NICOTINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 84949321486     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221945     Document Type: Article

References (72)

1. Ali SF, Newport RR, Holson W, Slikker W, Jr, and Bowyer JF (1995) Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice. Ann N Y Acad Sci 765:338.
2. Benowitz NL (1994) Biomarkers of cigarette smoking, smoking and tobacco control, in Monograph 7: The FTC Cigarette Test Method For Determining Tar, Nicotine and Carbon Monoxide Yields of U.S. Cigarettes, pp 93-111, National Institutes of Health, Bethesda, MD.
3. Benwell ME, Balfour DJ, and Anderson JM (1988) Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 50:1243-1247.
4. Bordia T, Campos C, Huang L, and Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327:239-247.
5. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Jr, and Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268:1571-1580.
6. Buisson B and Bertrand D (2002) Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 23: 130-136.
7. Breslau N and Peterson EL (1996) Smoking cessation in young adults: age at initiation of cigarette smoking and other suspected influences. Am J Public Health 86: 214-220.
8. Callaghan RC, Cunningham JK, Sajeev G, and Kish SJ (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25:2333-2339.
9. Callaghan RC, Cunningham JK, Sykes J, and Kish SJ (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120: 35-40.
10. Centers for Disease Control and Prevention (2002) Tobacco Information and Prevention Sources (TIPS), National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA.
11. Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, McIntosh JM, and Changeux JP (2002) Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 22: 1208-1217.
12. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, and Schatzkin A, et al. (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74:878-884.
13. Chen K and Kandel DB (1995) The natural history of drug use from adolescence to the mid-thirties in a general population sample. Am J Public Health 85:41-47.
14. Collins SL, Wade D, Ledon J, and Izenwasser S (2004) Neurochemical alterations produced by daily nicotine exposure in periadolescent vs. adult male rats. Eur J Pharmacol 502:75-85.
15. Colombo SF, Mazzo F, Pistillo F, and Gotti C (2013) Biogenesis, trafficking and upregulation of nicotinic ACh receptors. Biochem Pharmacol 86: 1063-1073.
16. Cubells JF, Rayport S, Rajendran G, and Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14: 2260-2271.
17. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, and Hanson GR (2015) Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend 146:30-38.
18. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
19. Dobbs LK and Mark GP (2008) Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. Neuroscience 156: 700-711.
20. Doura MB, Gold AB, Keller AB, and Perry DC (2008) Adult and periadolescent rats differ in expression of nicotinic cholinergic receptor subtypes and in the response of these subtypes to chronic nicotine exposure. Brain Res 1215:40-52.
21. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
22. Fleckenstein AE, Wilkins DG, Gibb JW, and Hanson GR (1997) Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther 283: 281-285.
23. Freed C, Revay R, Vaughan RA, Kriek E, Grant S, Uhl GR, and Kuhar MJ (1995) Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359:340-349.
24. García-Montes JR, Boronat-García A, López-Colomé AM, Bargas J, Guerra-Crespo M, and Drucker-Colín R (2012) Is nicotine protective against Parkinson's disease? An experimental analysis. CNS Neurol Disord Drug Targets 11:897-906.
25. Granado N, Ares-Santos S, and Moratalla R (2013) Methamphetamine and Parkinson's disease. Parkinsons Dis 2013:308052.
26. Grant KM, Kelley SS, Agrawal S, Meza JL, Meyer JR, and Romberger DJ (2007) Methamphetamine use in rural Midwesterners. Am J Addict 16:79-84.
27. Hadlock GC, Baucum AJ, 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, and Fleckenstein AE (2009) Mechanisms underlying methamphetamineinduced dopamine transporter complex formation. J Pharmacol Exp Ther 329: 169-174.
28. Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, and Fleckenstein AE (2009) Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment. Eur J Pharmacol 607:68-73.
29. Hernán MA, Takkouche B, Caamaño-Isorna F, and Gestal-Otero JJ (2002) A metaanalysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52:276-284.
30. Hernán MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, and Ascherio A (2001) Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 50:780-786.
31. Howard CD, Keefe KA, Garris PA, and Daberkow DP (2011) Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum. J Neurochem 118:668-676.
32. Huang LZ, Parameswaran N, Bordia T, Michael McIntosh J, and Quik M (2009) Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem 109:826-837.
33. Izenwasser S and Cox BM (1992) Inhibition of dopamine uptake by cocaine and nicotine: tolerance to chronic treatments. Brain Res 573:119-125.
34. Johnston LD, O'Malley PM, Miech RA, Bachman JG, and Schulenberg JE (2014) Monitoring the Future Results on Adolescent Drug Use: Overview of Key Findings, 2013, Institute for Social Research, University of Michigan, Ann Arbor, MI.
35. Kandel DB and Logan JA (1984) Patterns of drug use from adolescence to young adulthood: I. Periods of risk for initiation, continued use, and discontinuation. Am J Public Health 74:660-666.
36. Khwaja M, McCormack A, McIntosh JM, Di Monte DA, and Quik M (2007) Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2∗ nAChRs. J Neurochem 100:180-190.
37. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, and Furukawa Y (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131:120-131.
38. Kousik SM, Carvey PM, and Napier TC (2014) Methamphetamine self-administration results in persistent dopaminergic pathology: implications for Parkinson's disease risk and reward-seeking. Eur J Neurosci 40:2707-2714.
39. Kuryatov A, Luo J, Cooper J, and Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. Mol Pharmacol 68: 1839-1851. doi: 10.1124/mol.105.012419.
40. Lai A, Parameswaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, McIntosh JM, Grady SR, and Quik M (2005) Long-term nicotine treatment decreases striatal alpha 6∗ nicotinic acetylcholine receptor sites and function in mice. Mol Pharmacol 67: 1639-1647
41. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, and Arendash GW (1999) In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochim Biophys Acta 1454: 143-152.
42. Lotharius J and Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932-942.
43. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, and Corsini GU (1998) Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 71: 2439-2446.
44. Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, and Whiteaker P (2014) a6b2∗-subtype nicotinic acetylcholine receptors are more sensitive than a4b2∗-subtype receptors to regulation by chronic nicotine administration. J Neurochem 130:185-198.
45. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, and Collins AC (1992) Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J Neurosci 12:2765-2784.
46. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, and Donny EC, et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 190:269-319.
47. McCallum SE, Parameswaran N, Bordia T, Fan H, Tyndale RF, Langston JW, McIntosh JM, and Quik M (2006) Increases in alpha4∗ but not alpha3∗/alpha6∗ nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. J Neurochem 96:1028-1041.
48. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W, Alexander M, Dannals RF, and Wong DF, et al. (2008) Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62:91-100.
49. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, and Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417-8422.
50. McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, and Wilkins DG, et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303.
51. Meyer EL, Yoshikami D, and McIntosh JM (2008) The neuronal nicotinic acetylcholine receptors alpha 4∗ and alpha 6∗ differentially modulate dopamine release in mouse striatal slices. J Neurochem 105:1761-1769.
52. Northrop NA, Smith LP, Yamamoto BK, and Eyerman DJ (2011) Regulation of glutamate release by a7 nicotinic receptors: differential role in methamphetamineinduced damage to dopaminergic and serotonergic terminals. J Pharmacol Exp Ther 336:900-907.
53. O'Dell SJ, Galvez BA, Ball AJ, and Marshall JF (2012) Running wheel exercise ameliorates methamphetamine-induced damage to dopamine and serotonin terminals. Synapse 66: 71-80.
54. Obata T, Aomine M, Inada T, and Kinemuchi H (2002) Nicotine suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum. Neurosci Lett 330: 122-124.
55. Paxinos G and Watson C (2006) The Rat Brain in Stereotaxic Coordinates, 6th ed, Academic Press, London.
56. Perez XA, Bordia T, McIntosh JM, Grady SR, and Quik M (2008) Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2∗ and alpha6(nonalpha4) beta2∗ nAChR expression and function. Mol Pharmacol 74:844-853.
57. Quik M, Perez XA, and Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 27:947-957.
58. Quik M, Perez XA, and Grady SR (2011) Role of a6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders. Biochem Pharmacol 82:873-882.
59. Riddle EL, Fleckenstein AE, and Hanson GR (2006) Mechanisms of methamphetamineinduced dopaminergic neurotoxicity. AAPS J 8:E413-E418.
60. Ryan RE, Ross SA, Drago J, and Loiacono RE (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 132: 1650-1656.
61. Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, Changeux JP, and Corringer PJ (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 46: 595-607. doi: 10.1016/j.neuron.2005.03.029.
62. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, and Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
63. Sonsalla PK, Gibb JW, and Hanson GR (1986) Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 238:932-937.
64. Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24:417-463.
65. Tsai TH and Chen CF (1994) Simultaneous measurement of acetylcholine and monoamines by two serial on-line microdialysis systems: effects of methamphetamine on neurotransmitters release from the striatum of freely moving rats. The order of the author names in the manuscript is different from the cover sheet. Neurosci Lett 175-177.
66. Taguchi K, Atobe J, Kato M, Chuma T, Chikuma T, Shigenaga T, and Miyatake T (1998) The effect of methamphetamine on the release of acetylcholine in the rat striatum. Eur J Pharmacol 360: 131-137.
67. Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, and Kihara T, et al. (2009) Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J Neurosci Res 87:576-585.
68. Tirelli E, Laviola G, and Adriani W (2003) Ontogenesis of behavioral sensitization and conditioned place preference induced by psychostimulants in laboratory rodents. Neurosci Biobehav Rev 27:163-178.
69. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, and Fleckenstein AE (2005) Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. J Pharmacol Exp Ther 314:1087-1092.
70. Vieira-Brock PL, McFadden LM, Nielsen SM, Smith MD, Hanson GR, and Fleckenstein AE (2015) Nicotine administration attenuates methamphetamine-induced novel object recognition deficits. Int J Neuropsychopharmacol DOI: 10.1093/ijnp/pyv073 [published ahead of print].
71. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, and Ding YS, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
72. Whiteaker P, McIntosh JM, Luo S, Collins AC, and Marks MJ (2000) 125I-alphaconotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol Pharmacol 57:913-925.